LEVEL Phase 3 Misses Primary Endpoint

Company: Tenax Therapeutics · Event Type: Clinical/Regulatory Signal · Product/Asset: TNX-103 · Subject: PH-HFpEF · Event Date: August 10, 2026 Summary Tenax Therapeutics reported that the 241-patient Phase 3 LEVEL study of oral levosimendan, TNX-103, did not improve six-minute walk distance or the key Kansas…